Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...

Alvotech will conduct a business update conference call and live webcast on Thursday March 27, 2025, at 8:00 am ET (12:00pm ...

The Eylea franchise was in need of a win after an appellate court last week denied the pharma’s bid to block Amgen’s ...

Johnson & Johnson’s Stelara, Regeneron’s Eylea and Amgen’s Prolia are just some of the drugs facing off against new ...

Amgen has also opened a new technology and innovation site in ... appeals court upheld a decision denying a stay on sales of biosimilar versions of its drug Eylea, impacting its competitive stance in ...

Amgen’s AMGN stock has risen 21.7% so far this year compared with an increase of 7% for the industry. AMGN Stock Performance Image Source: Zacks Investment Research Amgen’s stock has been rising ...

Amgen has also opened a new technology and innovation ... denying a stay on sales of biosimilar versions of its drug Eylea, impacting its competitive stance in the biologics market.

The appeals court for the Federal Circuit upheld a lower court’s ruling, finding that Regeneron has not sufficiently established that Amgen’s biosimilar Pavblu violates key patents of Eylea. A U.S.

The US Court of Ap­peals for the Fed­er­al Cir­cuit on Fri­day ruled against Re­gen­eron in a close­ly-watched patent in­fringe­ment case in­volv­ing the New York biotech’ … ...

The once-fledg­ling field of MASH drug de­vel­op­ers is now one of the few ar­eas of con­sis­ten­cy in the biotech in­dus­try.

Adds Regeneron comment Regeneron Pharmaceuticals (NASDAQ:REGN) dropped 1.6% after the company's loss against Amgen (NASDAQ:AMGN) in a patent case over Regeneron's blockbuster Eylea drug was affirmed ...